PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2020; 10(02): 74-78
DOI: 10.1055/s-0040-1714650
Original Article

Diagnostic Performance of Xpert MTB/RIF in Bronchoalveolar Lavage of Sputum-Scarce Recurrent Pulmonary Tuberculosis Cases

Pratibha Sharma
1   Department of Microbiology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
,
Abhishek Kumar
2   Department of Pulmonary Medicine, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India
,
Mamatha S.
3   Department of Respiratory Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India
,
Ranganath T. Ganga
4   Department of Pulmonary Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Introduction Xpert MTB/RIF has greater sensitivity and specificity than smear microscopy. Bronchoalveolar lavage (BAL) is safe and valuable tool in sputum-scarce and sputum-negative tuberculosis (TB) patients. Our study evaluated the performance of Xpert in BAL specimen of sputum-scarce recurrent TB cases exclusively.

Materials and Methods Sputum-scarce recurrent TB patients who underwent BAL between July 2018 and July 2019 were included. The diagnostic performance of Xpert and acid-fast bacilli (AFB) smear examination in BAL specimen was compared with liquid culture Mycobacterium TB (MTB) and composite reference standard.

Results A total of 126 patients were included in the study. MTB culture was positive in 70 cases and nontuberculous mycobacteria were seen in five cases. Xpert was positive was in 63 patients. Sensitivity of Xpert and AFB smear was 84.29% (95% confidence interval [CI]: 73.62–91.89) and 18.57% (95% CI: 10.28–29.66), respectively, with p < 0.001 proving the superiority of Xpert. Xpert had a specificity of 97.96 (89.15–99.95), positive predictive value of 93.65% (95% CI 85.19–97.42), and negative predictive value of 80.36% (95% CI: 70.26–87.63). Smear had a specificity of 91.84% (95% CI: 80.21–97.58) against 97.96 (89.15–99.95) of Xpert, and smear was positive in nontuberculous mycobacterium cases as well. Xpert showed no cross-reactivity between mycobacterial species. Rifampicin resistance was seen in 8 (12.69%) cases, and 21 patients had other diagnoses.

Conclusion Xpert has greater sensitivity in comparison to AFB smear in BAL specimen. Sputum-scarce recurrent TB cases have a similar chance of rifampicin resistance as sputum smear-positive cases should undergo BAL for Xpert analysis routinely.

Keywords

bronchoalveolar lavage - pulmonary tuberculosis - recurrent tuberculosis - sputum-scarce pulmonary tuberculosis - tuberculosis - Xpert MTB/RIF


Publikationsverlauf

Artikel online veröffentlicht:
03. August 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 World Health Organization. Global Tuberculosis Report 2019. Available at: https://www.who.int/tb/publications/global_report/en/. Accessed June 24, 2020
  • 2 Central TB Division. India TB report 2019. https://tbcindia.gov.in/WriteReadData/India%20TB%20Report%202019.pdf. Accessed June 24, 2020
  • 3 de Gracia J, Curull V, Vidal R. et al. Diagnostic value of bronchoalveolar lavage in suspected pulmonary tuberculosis. Chest 1988; 93 (02) 329-332
    CrossrefPubMedSuche in Google Scholar
  • 4 Theron G, Peter J, Meldau R. et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013; 68 (11) 1043-1051
    CrossrefPubMedSuche in Google Scholar
  • 5 Khalil KF, Butt T. Diagnostic yield of bronchoalveolar lavage gene Xpert in smear-negative and sputum-scarce pulmonary tuberculosis. J Coll Physicians Surg Pak 2015; 25 (02) 115-118
    PubMedSuche in Google Scholar
  • 6 Pan X, Yang S, Deighton MA, Qu Y, Hong L, Su F. A Comprehensive evaluation of Xpert MTB/RIF assay with bronchoalveolar lavage fluid as a single test or combined with conventional assays for diagnosis of pulmonary tuberculosis in China: a two-center prospective study. Front Microbiol 2018; 9: 444
    CrossrefPubMedSuche in Google Scholar
  • 7 Lee HY, Seong MW, Park SS. et al. Diagnostic accuracy of Xpert® MTB/RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis. Int J Tuberc Lung Dis 2013; 17 (07) 917-921
    CrossrefPubMedSuche in Google Scholar
  • 8 Barnard DA, Irusen EM, Bruwer JW. et al. The utility of Xpert MTB/RIF performed on bronchial washings obtained in patients with suspected pulmonary tuberculosis in a high prevalence setting. BMC Pulm Med 2015; 15: 103
    CrossrefPubMedSuche in Google Scholar
  • 9 Mishra G, Mulani J. First National Anti-Tuberculosis Drug Resistance Survey (NDRS) from India - an eye opener. J Infect 2018; 1 (02) 26-29
    Suche in Google Scholar
  • 10 Chambers HF, Moreau D, Yajko D. et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?. Antimicrob Agents Chemother 1995; 39 (12) 2620-2624
    CrossrefPubMedSuche in Google Scholar
  • 11 Pagliotto ADF, Caleffi-Ferracioli KR, Lopes MA. et al. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination. J Microbiol Immunol Infect 2016; 49 (06) 980-983
    CrossrefPubMedSuche in Google Scholar
  • 12 Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?. Expert Rev Mol Diagn 2010; 10 (07) 937-946
    CrossrefPubMedSuche in Google Scholar
  • 13 Friedrich SO, Rachow A, Saathoff E. et al. Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013; 1 (06) 462-470
    CrossrefPubMedSuche in Google Scholar
  • 14 Jani MN, Rodrigues CS, Mehta AP. The neglected and often ignored: nontuberculous mycobacteria. J Glob Infect Dis 2011; 3 (01) 94
    CrossrefPubMedSuche in Google Scholar
  • 15 Jesudason MV, Gladstone P. Non tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital in South India. Indian J Med Microbiol 2005; 23 (03) 172-175
    CrossrefPubMedSuche in Google Scholar
  • 16 Jain S, Sankar MM, Sharma N, Singh S, Chugh TD. High prevalence of non-tuberculous mycobacterial disease among non-HIV infected individuals in a TB endemic country–experience from a tertiary center in Delhi, India. Pathog Glob Health 2014; 108 (02) 118-122
    CrossrefPubMedSuche in Google Scholar
  • 17 Blakemore R, Story E, Helb D. et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 48 (07) 2495-2501
    CrossrefPubMedSuche in Google Scholar
  • 18 Helb D, Jones M, Story E. et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48 (01) 229-237
    CrossrefPubMedSuche in Google Scholar
  • 19 Boondireke S, Mungthin M, Tan-ariya P. et al. Evaluation of sensitivity of multiplex PCR for detection of Mycobacterium tuberculosis and Pneumocystis jirovecii in clinical samples. J Clin Microbiol 2010; 48 (09) 3165-3168
    CrossrefPubMedSuche in Google Scholar
  • 20 Osei Sekyere J, Maphalala N, Malinga LA, Mbelle NM, Maningi NE. A Comparative evaluation of the new Genexpert MTB/RIF Ultra and other rapid diagnostic assays for detecting tuberculosis in pulmonary and extra pulmonary specimens. Sci Rep 2019; 9 (01) 16587
    CrossrefPubMedSuche in Google Scholar